- SENIOR FACULTY Medicine, Cardiology
- Cardiovascular Disease
- Nuclear Cardiology
MD, Jefferson Medical College
MBA, NYU Stern School of Business
Medical Internship, The Mount Sinai Hospital
Cardiology Fellowship, Albert Einstein College of Medicine
Residency, Internal Medicine
Mount Sinai Hospital
Montefiore Medical Center
Dr. Blaufarb is a passionate and gentle physician with a particular interest in women’s cardiac health. His patients love his ability to translate complex cardiac conditions into understandable terms as well as his natural gift to encourage and comfort. Dr. Blaufarb is an avid cyclist with a keen business sense evidenced by his recent completion of the NYU Stern Executive MBA program.
Dr. Blaufarb received his Bachelor of Science from Union College and his Doctor of Medicine from Jefferson Medical College. He completed his residency at Mt. Sinai Hospital in New York, and a fellowship in cardiology at the Albert Einstein College of Medicine. From 1995 to 1996, and Dr. Blaufarb was the Administrative Chief Fellow in the Division of Cardiology at Albert Einstein College of Medicine. Dr Blaufarb is board certified in Cardiovascular Disease and Nuclear Cardiology. In addition to acting as an Associate Professor at Mount Sinai, Dr. Blaufarb is also on staff at Lenox Hill Hospital.
Blaufarb I, Pfeifer TM, Frishman WH. beta-blockers. Drug interactions of clinical significance. Drug safety : an international journal of medical toxicology and drug experience 1995 Dec; 13(6).
Blaufarb IS, Sonnenblick EH. The renin-angiotensin system in left ventricular remodeling. The American journal of cardiology 1996 May; 77(13).
Hamroff G, Blaufarb I, Mancini D, Katz SD, Bijou R, Jondeau G, Olivari MT, Thomas S, LeJemtel TH. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. Journal of cardiovascular pharmacology 1997 Oct; 30(4).
Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari MT, Thomas S, Le Jemtel TH. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999 Mar; 99(8).
Frishman W, Sonnenblick E. Antiplatelet and Anticoagulant Therapy in Cardiovascular Disease. In: Cardiovascular Pharmacotherapeutics. McGraw-Hill;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Blaufarb did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
638 Columbus Avenue
New York, NY 10024
177 E87th Street
New York, NY 10128
638 Columbus Avenue
New York, NY 10024
- Monday 10:00am - 6:00pm
- Tuesday 10:00am - 6:00pm
- Wednesday 10:00am - 6:00pm
- Thursday 10:00am - 6:00pm
- Friday 10:00am - 6:00pm